anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE:An immune adjusting agent useful for preventing and remedying autoimmune disease, allergic disease, etc., having immunosuppressive action in contrast with vitamin E, comprising a chroman compound or its ester as an active ingredient. CONSTITUTION:An immune adjusting agent comprising a chroman compound shown by the formula I (R is 1-11C alkyl), or its ester as an active ingredient. 2,2,5,7,8-pentamethyl-6-chromanol shown by the formula II, etc. may be cited as the concrete example of the compound shown by the formula I . The compound shown by the formula I has immunosuppressive action, whereas vitamin E has immune enhancing action, and the compound is useful as an immune adjusting agent. It can be used for preventing and remedying autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, allergic diseases such as asthma, allergic rhinitis, etc., Hashimoto's disease accompanied by endocrine abnormality, hypoparathyroidism, etc. A dose is in a range of 0.1-100mg/kg.
The invention discloses an indolic acid derivative for relieving colonitis and application thereof. The 5-methoxy-2-methyl-3-indoleacetic acid (DES) provided by the invention has no toxic or side effect on animals. The DES provided by the invention can obviously reduce DAI index of mice during DSS induced colonitis and lighten the shortening of colon. The DES provided by the invention can relieve obvious damage to colon tissues of mice induced by DSS, wherein the obvious damage comprises replacement of individual intestinal gland disappearance by proliferated connective tissue, reduction of goblet cell quantity and small quantity of lymphocyte infiltration around the mice. The concentrations of the pro-inflammatory cytokines TNF- α, IL-6, IL-8 and IL-1β were significantly reduced in colon tissue of DES-intervention group mice compared to model group mice. DES intervention reduces serum immunoglobulin IgA, igG concentrations.
Antipsychotic drugs are widely used to treat not only psychosis but an increasing number of other psychiatric indications. The prevalence of antipsychotic drug use in British Columbia is increasing at a high rate, especially in youth. Second generation ("atypical") antipsychotic drugs, while bereft of the neurological side-effects of their predecessors, commonly cause metabolic syndrome. This includes hyperglycemia, hyperlipidemia, insulin resistance, weight gain and hypertension - a cluster of side-effects that puts patients at strongly increased risk of cardiometabolic disorders such as Type 2 diabetes and cardiovascular disease. Drug therapies to reduce metabolic dysregulation have provided limited benefits. It is recognized that lifestyle changes that address daily habits regarding eating, physical exercise, stress and sleep management, and lifestyle habits such as smoking, represent a complementary approach to additional drug therapy. The emerging field of Integrative Health Coaching addresses this issue and provides a clinical framework for helping people successfully develop and achieve personalized lifestyle goals. This study will investigate whether Health Coaching is a useful clinical tool to facilitate healthy lifestyle behavior and thereby improve metabolic health in people with psychotic illness.

HYPOTHESIS: In a first-episode psychosis population that have recently begun treatment with atypical antipsychotic drugs, the inclusion of an Integrative Health Coaching goal-setting model will significantly improve patients' attitudes towards, and increase the frequency of behaviours related to healthy living, as indicated by the Short-Form 36, the Three-Factor Eating Questionnaire, and the Health Value Scale.

RESEARCH PLAN: The investigators will conduct a non-blinded clinical trial of the efficacy of Integrative Health Coaching techniques in 40 subjects who are being treated at the Vancouver/Richmond Early Psychosis Intervention program, which provides specialty care to patients with suspected or newly diagnosed psychotic disorders. All subjects will be randomly assigned to one of two treatment groups (n = 20 subjects per group). In the first group, subjects will receive treatment for psychosis based on the current standard of care, which includes psychosocial training, education and pharmacological treatment. The second group of subjects will receive not only the standard of care treatment for psychosis, but additional Health Coaching to improve physical health. Subjects in both treatment groups will be given questionnaires to assess health attitudes and behaviours, and will receive routine blood work to monitor metabolic dysregulation, at baseline and months 1, 2, 3 and 6 from when they enter the study. Data will be collected and analyzed for differences between the two groups at the end of the study. Results will be analyzed based on intent-to-treat analysis, and comparison of metabolic and other health indices compared between the two groups using t-test and chi-square analyses.
The invention discloses a sclerotium oyster-cap fungus donghua tiger milk number 1bacterial strain and it application. The bacterial strain belongs to basidiomycetes oyster-cap fungus section, alternate name is tiger-milk bacterium, nuclear ear mushroom,poria cocos wolf oyster-cap fungus, nanyang oyster-cap fungus and it is preserved on September 25th, 2005 year whose entreasure identification serial number is CGMCC No.1545. It has strong anti- polygamy, bacterial filament upgrowth temperature is 18 to 38 DEG C and the most suitable temperature is 24 to 27 DEG C, bacterial filament upgrowth ph is 5.5 to 6.8 and the most suitable Ph is 5.8 to 6.5. The bacterial strain is a typical high temperature variety which can grow in simple shade in hot summer. The fresh mushroom has delicious flavor, good mouthfeel and keeping quality identity and the dried mushroom has good color and fragrance. The sclerotium oyster-cap fungus donghua tiger milk number 1 has abundant nutrition ingredient and is not only edible but also a treasure dual purpose large scale fungi both for food and medicine. Also the fungi is an excellent health care food and has the function of prolong life and health care beauty treatment for elder on condition of long-term consumption.
The development of in vitro models is essential for a comprehensive understanding and investigation of pulmonary fibrosis (PF) at both cellular and molecular levels. This study presents a literature review and an analysis of various cellular models used in scientific studies, specifically focusing on their applications in elucidating the pathogenesis of PF. Our study highlights the importance of taking a comprehensive approach to studing PF, emphasizing the necessity of considering multiple cell types and organs and integrating diverse analytical perspectives. Notably, primary cells demonstrate remarkable cell growth characteristics and gene expression profiles; however, their limited availability, maintenance challenges, inability for continuous propagation and susceptibility to phenotypic changes over time significantly limit their utility in scientific investigation. By contrast, immortalized cell lines are easily accessible, cultured and continuously propagated, although they may have some phenotypic differences from primary cells. Furthermore, in vitro coculture models offer a more practical and precise method to explore complex interactions among cells, tissues and organs. Consequently, when developing models of PF, researchers should thoroughly assess the advantages, limitations and relevant mechanisms of different cell models to ensure their selection is consistent with the research objectives.
Toxoids are obtained from purified bacterial toxins by treating said toxins in an aqueous medium with formaldehyde in the presence of an aliphatic diamine of molecular weight below 200 which contains a primary or secondary amino group. The toxoids are believed to be represented by the formula [t] (CH2.Y)n, in which [t] represents the radical formed from a bacterial toxin molecule by the loss of one or more hydrogen atoms on groups reactive with formaldehyde, Y represents the radical formed by the loss of a hydrogen atom from an amino group of a molecule of an aliphatic diamine of molecular weight below 200, and n is a positive number. Specified aliphatic diamines, as defined above, are lysine and ethylenediamine. The said aliphatic diamines may be used in admixture with other amines, e.g. alanine. Examples illustrate the preparation of diphtheria toxoids, aqueous solutions of which may be used as diphtheria vaccines, including diphtheria-tetanus and diphtheria-pertussiotetanus vaccines. According to the Provisional Specification, arginine is a further example of a suitable aliphatic diamine, as defined above.
An estimated one in four teen women will become pregnant by the time she is 20 years of age. That said, significant disparity in rates exist for lesbian, gay, bisexual and other sexual minority women (LGB) versus non-LGB teen women: Research suggests that lesbian and bisexual teen women are between two and four times more likely to report having been pregnant than teen women who identified as exclusively heterosexual. Despite this compelling evidence that lesbian and bisexual adolescent women are at risk for teen pregnancy, programs tailored to the unique needs of adolescent LGB women are nonexistent. Evidence-based teen pregnancy prevention (TPP) programs targeting LGB teen women are urgently needed.

The Girl2Girl intervention text messaging-based TPP program designed specifically for LGB women ages 14-18 years, nation-wide. This is an extension of a previous randomized controlled trial. Here, the cohort was recruited using an effectiveness strategy: Girls were allowed to register and enroll themselves without needing to talk to research staff. All eligible and interested youth were allowed to enroll; no diversity targets were applied.
The objectives of the thesis are to determine the effects of ashwagandha (ASH) on muscle strength, muscle recovery and to assess habitual dietary intake of female footballers. Across one phase, two experimental research papers and one descriptive research paper will be produced; it will involve one double-blind, randomised and placebo-controlled trial and a comparative analysis of nutritional intake in female footballers. The thesis will involve participants supplementing ASH in the form of a capsule containing KSM-66 (600 mg with 30mg withanolides) or placebo once a day for 28 days, on a singular occasion. The objectives of the first two papers are to determine the effects of ASH on muscle strength, perception of recovery, perception of exertion, perceived wellness and perceived muscle soreness. For the paper on muscle strength, the methodology will include hand grip test, counter movement jump (CMJ), squat jump (SJ), peak power, medicine ball throw and rate of perceived exertion (RPE) via the Borg Scale. For the paper on muscle recovery, the methodology will include a questionnaire on sleep, stress, fatigue and delayed onset of muscle soreness (DOMS) test via the Hooper Index (HI), total quality recovery (TQR) questionnaire and a supplement satisfaction questionnaire. The objectives of the third paper are to evaluate the dietary intake of professional female footballers and compare the values against published nutritional recommendations. The participants diets will be tracked for purposes of the muscle strength and recovery study. The methodology will involve self-tracking of dietary intake via the Snap-N-Send method and data will be stored and analysed with the software Nutritics. The study will be conducted with a professional club in Barcelona. The use of ASH is becoming prevalent in athletes, despite lack of information regarding dosage guidelines or lack of research on its benefits for exercise performance. The proposed study will contribute to the overall scientific knowledge of ASH and whether it may demonstrate benefits from short-term use. Additionally, the study will determine if there are benefits for female athletes that wish to increase strength and reduce perception of pain or soreness related to exercise. The ethical considerations for this study are predominantly the safety and comfort of the participant. An informed consent form will be given to the participant, containing information about data collection, personal information, safety of the supplement and their right to drop out of the study at any point. The proposed start date is January 2024, and the study will aim to collectively last for 36 days across a singular phase. The supplement is provided by Zenement España, a supplement company based in Barcelona.
<P>PROBLEM TO BE SOLVED: To provide a new method for producing a phosphorus-substituted porphyrin compound, by which various kinds of phosphorous functional groups can freely be introduced into the porphyrin ring.  <P>SOLUTION: This method for producing the phosphine-substituted porphyrin compound is characterized by coupling-reacting a halogen-substituted porphyrin compound with a secondary phosphine in the presence of a transition metal as a catalyst. The phosphine-substituted porphyrin compound can be subjected to a reaction such as an oxidation reaction to convert into the phosphine oxide-substituted porphyrin compound. The halogen-substituted porphyrin compound can be coupled with a phosphite in the presence of a transition metal as a catalyst to produce the phosphonate-substituted porphyrin compound. The phosphonate-substituted porphyrin compound can be subjected to a reaction such as an ester-eliminating reaction to convert into the phosphonate-substituted porphyrin compound.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Patients received 3.5g oral omega-3 fatty acid daily for 6 months. Questionnaire administration, pills counts, and medication diaries were collected at monthly intervals.
ETHNOPHARMACOLOGICAL RELEVANCE: Cyperus articulatus L., popularly known as priprioca, is a plant used in the Amazon for perfumed baths and homemade perfumes. In traditional medicine, its rhizomes are used to treat diseases related to inflammatory processes.
AIM OF THE STUDY: Due to its promising bioactive properties, this study sought to investigate its phytochemistry and the anti-inflammatory and antinociceptive activity of the essential oil obtained from C. articulatus (CAEO) in in vitro and in vivo tests.
MATERIAL AND METHODS: The essential oil was obtained from the rhizomes of C. articulatus and extraction was carried out via hydrodistillation. Then, the oil was analyzed by GC-MS analyses. Initially, culture of RAW 264.7 macrophages stimulated by lipopolysaccharide (LPS) was used to evaluate cytotoxicity and interference in the production of mediators of the inflammatory process (nitrite, IL-1β, TNF-α and PGE2) after exposure to CAEO. The acute toxicity of CAEO was evaluated and the results were used to define doses of 10, 100 and 400 mg kg-1 for evaluation of CAEO in in vivo tests using mice. The carrageenan-induced air pouch models and the Evans test were used to evaluate the anti-inflammatory activity by measuring the number of total leukocytes and vascular permeability. Antinociceptive activity was evaluated via tests of contortions induced by acetic acid, hot plate, and formalin.
RESULTS: Treatment with CAEO reduced the levels of nitrite IL-1β, TNF-α and PGE2 in the macrophage culture, revealing its anti-inflammatory potential. CAEO decreased carrageenan-induced leukocyte migration and vascular permeability, which are important events related to the acute inflammatory response. Nociceptive activity was significantly inhibited by CAEO in the acetic acid-induced contortions model, hot plate, and in both phases of the formalin test. The treatment with naloxane reversed the antinociceptive effect observed in the formalin test, suggesting the participation of opioid receptors in the mechanism of action of CAEO.
CONCLUSION: The observed results reveal the anti-inflammatory and antinocipeptive activity of C. articulatus essential oil in vivo and support the traditional use of this plant in the treatment of different diseases involving inflammation and pain.
Nivolumab give by IV over 60 minutes on days 1 and 15, rituximab IV on day 1, and lenalidomide by mouth once per day on days 1-21. Repeats every 28 days for up to of 8 courses in the absence of disease progression or unacceptable toxicity. Patients with partial response or stable disease at the end of 8 cycles will be offered lenalidomide and nivolumab maintenance for up to 12 courses.
Patients receive ipilimumab IV over 90 minutes and anti-GITR agonistic monoclonal antibody BMS-986156 IV over 60 minutes on day 1. Treatment repeats every 21 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity. After completion of cycle 2, patients then undergo SBRT on days 29-32 for 4 fractions or on days 29-40 for 10 fractions. Beginning day 1 of cycle 5 (day 85), patents receive nivolumab IV over 30 minutes. Treatment repeats every 28 days for up to 26 cycles in the absence of disease progression or unacceptable toxicity.
This is a non-randomized, multi-center, open-label, Phase Ⅰb/Ⅱ clinical trial. For phase Ⅰb, patients must have a histologically confirmed diagnosis of advanced soft tissue sarcomas (including malignant PEComa, accounting for at least 1/2) that have failed standard treatment (disease progression or relapse or intolerance, such as chemotherapy, radiotherapy, targeted therapy, etc.) or lack effective treatment. The recommended phase II dose (RP2D) will be determined in phase Ⅰb. For phase Ⅱ, patients must have a histologically confirmed diagnosis of malignant PEComa that is either metastatic or locally advanced and for which surgery is not a recommended option. Phase Ⅱ will use the recommended dose and dosing regimen from Phase Ⅰb.
STSG is a reconstructive procedure that is most used for management of burn injuries. Skin harvesting creates a new partial thickness wound, a donor site that causes additional pain for the patient during the postoperative recovery. Therefore, and because wound healing complications, such as delayed healing and infections, are common donor sites, the donor sites are problematic to treat. A dressing that wound provide optimal healing, low costs, and minimal pain with few dressing changes would be a preferred choice for treatment of donor sites. NFC wound dress, like FibDex, are used for providing these kinds of benefits to patients and better healing result.

This is a sponsored prospective, randomized, controlled, non-blinded, non-inferiority study. Subjects will be treated with the IMD or the comparator and act as their own controls. Subjects will be followed up for up to POD 365. Purpose of this PMCF study for FibDex is to gather data for updating the clinical evaluation and assess if new data gained over time has a bearing on the risk-benefit assessment or if there are some needs to make changes to the product or the package. Clinical evaluation is ongoing and happens throughout the medical devices lifetime. Clinical safety need to be analyzed periodically according to MDR requirements. For class IIb products, like FibDex, it means clinical safety update every year. This study is part of that evaluation.

Aim is to get 48 randomized STSG wounds. Study methods during this study are using the IMD or the comparator after the surgery, subject diaries, pain questionnaires, scar quality assessments by investigator and study subjects and visual observation by the delegated site staff. Also, photos of the healing process will be collected.
PURPOSE:An improve remedy for ulcer, capable of being synthesized easily, having low toxicity and low side effects, comprising a dipeptide consisting of two amino acids selected from glycine, serine, histidine, and lysine or its salt as an active ingredient. CONSTITUTION:A remedy for ulcer comprising at least one of a dipeptide (e.g., glycylserine, serylhistidine, histidyllysine, etc.) consisting of two amino acids selected from glycine, serine, histidine, and lysine, and its salt. Especially a dipeptide having glycine, serine or histidine as an N-terminal amino acid, and serine, histidine, or lysine as a C-terminal amino acid is preferable as the dipeptide. The dipeptide may be cyclic. The dipeptide of this invention showing improved antiulcer action, and useful as a preventive or remedy for peptic ulcers of digestive system, aphthous stomatitis, burn, etc.
Folic acid (\~400 µg/day) taken around the time of conception significantly reduces the risk of a neural tube defect (NTD)-affected pregnancy. Strategies to reduce NTD with folic acid, include supplement use and food fortification. An attractive strategy for NTD prevention is the use of fortified foods targeted for use by women planning a pregnancy. Fonterra currently markets a fortified-milk (ANMUM Materna) in Asia, designed for use prior to and during pregnancy. This milk product, if consumed as directed, provides \~400 µg folic acid per day. It is not known whether ANMUM Materna will reduce NTD rate. However, in a case-control study the risk of NTD was inversely associated with maternal red blood cell (RBC) folate concentrations. Accordingly, if ANMUM Materna increases RBC folate, it could be expected to decrease NTD risk.

In this study, the ANMUM Materna fortified milk will be tested against a standard control (unfortified) milk over a 12 week period. The subjects will consume 75g of milk powder daily throughout the supplementation period.
The current standard for breast augmentation involves placement of an implant. Although implants are safe, they are foreign bodies and thus have inherent risks including infection, failure, malposition, etc. In order to avoid the inherent risks of an implanted device, some surgeons and patients have elected to proceed with breast augmentation from autologous tissue. Early reports of autologous fat transplantation to the breasts were successful, but increases in breast volume were modest (Bircoll, 1987). There were also hypothetical concerns about changes in the breast tissue that would interfere with mammographic screening for breast cancer.

Spear et al (2005) performed autologous fat transplantation to reconstructed breasts in 37 patients with 2-dimensional photographic evidence of improved breast shape and volume suggesting that this technique can be effectively performed. However, these patients had all received mastectomies so mammographic screening was not indicated. Coleman and Saboeiro (2007) performed autologous fat transplantation to the breasts in 17 patients. Fifteen of the 17 patients received post-operative mammograms, 7 (47%) of which were abnormal. However, none of these abnormal findings interfered with cancer screening. Furthermore, 2 patients in the study did develop breast cancer which was successfully detected by mammography. Other studies have confirmed the ability to differentiate benign from malignant findings on mammogram after autologous fat transplantation. Pulagam et al (2006) reported long term (10 and 8 year) findings on 2 patients that underwent autologous fat transplantation to the breasts. Mammography and ultrasound were used to differentiate benign from malignant appearing calcifications. Some authors have speculated that autologous fat transplantation to the breast would lead to mammographic changes similar to routine breast procedures such as breast reduction and mastopexy (Coleman and Saboeiro, 2007).
PURPOSE: A method of manufacturing an Acanthopanacis Cortex extract having inhibition effects on proliferation of osteoblast and osteoclast is provided. A pharmaceutical composition and a health food composition for the prevention and treatment of osteoporosis contain the Acanthopanacis Cortex extract as an active ingredient. CONSTITUTION: Acanthopanacis Cortex containing Acanthopanax Senticosus(Rupr. et Maxim.) Harms, Acanthopanax sessiliflorus Seem. or the like is characteristically extracted in water or an aqueous alcohol solution. The aqueous alcohol solution is selected from the group consisting of 5 to 10% ethyl alcohol or 5 to 100% methyl alcohol. The Acanthopanacis Cortex extract can be effectively used in prevention and treatment of osteoporosis, bone degenerative diseases and rheumatoid arthritis.